Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL5141132 | 0.79 | PDPK1 (0.50) | TLR7 | |
| 2,6-Diaminopurine SCHEMBL5141130 | 0.79 | TLR7 (0.37) | TLR7 | |
| SCHEMBL13851087 | 0.79 | HPGD (0.51) | TLR7 | |
| SCHEMBL13850519 | 0.79 | TLR7 (0.47) | TLR7 | |
| SCHEMBL22911735 | 0.76 | TLR7 (0.53) | TLR7 | |
| SCHEMBL8440057 | 0.75 | TLR7 (0.50) | TLR7 | |
| SCHEMBL338431 | 0.75 | PNP (0.61) | TLR7 | |
| SCHEMBL8438778 | 0.73 | TLR7 (0.43) | TLR7 | |
| SCHEMBL8437308 | 0.73 | TK1 (0.51) | TLR7 | |
| SCHEMBL8439273 | 0.72 | TLR7 (0.43) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188254-B2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| EP-1730281-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | Coley Pharmaceutical Group, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| EP-1678303-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical GmbH (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005111057-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050239734-A1 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1578954-A2 | 5' CPG NUCLEIC ACIDS AND METHODS OF USE | Coley Pharmaceutical Group, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005042018-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20040171571-A1 | 5' CpG nucleic acids and methods of use | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-09-02 | — | — | US | claimed |
| WO-2004053104-A2 | 5’ CPG NUCLEIC ACIDS AND METHODS OF USE | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-12637646-B2 | DNA origami cell sensing platform | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | GIGAMUNE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12631622-B2 | Ligand discovery and gene delivery via retroviral surface display | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12631621-B2 | Ligand discovery and gene delivery via retroviral surface display | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12611455-B2 | DNA nanostructure-based vaccines | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2004039829-A2 | USE OF CPG OLIGONUCLEOTIDES IN THE TREATMENT OF HEPATITIS C VIRUS INFECTION | COLEY PHARMACEUTICAL GROUP, LTD. (CA) | 2004-05-13 | — | — | WO | disclosed |
| US-20040092472-A1 | Nucleic acid compositions for stimulating immune responses | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040067905-A1 | Nucleic acid compositions for stimulating immune responses | COLEY PHARMACEUTICAL GROUP, INC. | 2004-04-08 | — | — | US | disclosed |
| US-20040053880-A1 | Nucleic acid compositions for stimulating immune responses | COLEY PHARMACEUTICAL GROUP, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611455-B2 | DNA nanostructure-based vaccines | TLR9, TLR1, TLR8 | TLR7 4/4885 |
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | TMIGD3, TMPRSS11D, TMED2 | TLR7 3835/4885 |
| US-12631622-B2 | Ligand discovery and gene delivery via retroviral surface display | VSIG8, TMIGD3, CD4 | TLR7 521/4885 |
| US-12637646-B2 | DNA origami cell sensing platform | DNMT3A, EPCAM, CASR | TLR7 1343/4885 |
| US-12631621-B2 | Ligand discovery and gene delivery via retroviral surface display | TMIGD3, LDLR, VSIG8 | TLR7 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.